Asad Haider
Stock Analyst at Goldman Sachs
(1.67)
# 2,459
Out of 4,944 analysts
7
Total ratings
50%
Success rate
1.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Initiates: Neutral | $27 | $25.76 | +4.81% | 1 | Jul 17, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $112.78 | -2.46% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $174.42 | -1.39% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $660.49 | +34.45% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $201.47 | -3.71% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $47.85 | +14.94% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.16 | -0.64% | 1 | Apr 8, 2025 |
NewAmsterdam Pharma Company
Jul 17, 2025
Initiates: Neutral
Price Target: $27
Current: $25.76
Upside: +4.81%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $112.78
Upside: -2.46%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $174.42
Upside: -1.39%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $660.49
Upside: +34.45%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $201.47
Upside: -3.71%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $47.85
Upside: +14.94%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.16
Upside: -0.64%